Search Results

Business

Amphista Therapeutics Expands Senior Team and Announces Appointment of Louise Modis as Chief Scientific Officer and Ian Churcher as Chief Technology Officer

Amphista Therapeutics announced that Louise Modis, PhD, has joined the company as Chief Scientific Officer and Ian Churcher, DPhil, will transition to the role of Chief Technology Officer.

May 2, 2023

·

2 min read

Genetown

Affinia Therapeutics to Participate in the 2024 Jefferies Global Healthcare Conference

Affinia Therapeutics today announced that Rick Modi , Affinia’s Chief Executive Officer, and Laura Richman, MBA, D.V.M., Ph.D., D.A. will participate in one-on-one meetings with investors at the 2024 Jefferies Global Healthcare Conference on Tuesday, June 4, 2024 in New York, NY.

May 28, 2024

·

1 min read

Business

jCyte Announces Expansion of Role for Chief Commercial Officer Samir Mody

jCyte, Inc. today announced the expansion of the role of Dr. Samir Mody. In addition to his Chief Commercial Officer responsibilities focused on preparing for the North American launch of jCell, Dr. Mody will now also assume leadership for the Global Pricing, Health Economics, and Reimbursement functions for jCyte.

October 14, 2021

·

4 min read

Business

Mogrify Strengthens Executive Leadership Team with the Appointment of Louise Modis as Chief Scientific Officer

Mogrify Limited, a biopharmaceutical company pioneering the development of a new class of in vivo reprogramming therapies and transforming the development of ex vivo cell therapies, announced the appointment of Dr. Louise Modis as Chief Scientific Officer, following the recent completion of a $33 million USD Series A funding.

October 5, 2021

·

2 min read

Business

Modis Therapeutics Announces Appointment of Matthew R. Patterson to Board of Directors

Modis Therapeutics announced today that Matthew R. Patterson, co-founder and Chief Executive Officer of Audentes Therapeutics, has joined Modis’ Board of Directors.

October 29, 2018

·

2 min read

Pharm Country

VBL Therapeutics Announces Closing of Sale of Manufacturing Facility and Certain Related Assets for $7.1 Million in Cash

VBL Therapeutics announced that it has closed on the previously announced sale of its manufacturing facility in Modi’in, Israel, and certain related assets, for $7.1 million in cash to Aleph Farms, an Israel-based food technology company.

March 9, 2023

·

5 min read

Deals

Aleph Farms Increases Production Capabilities with VBL Therapeutics Facility Acquisition and ESCO Aster Partnership

Aleph Farms, the first company to grow cultivated steaks directly from non-modified cow cells, announced that it has acquired a manufacturing facility in Modi’in, Israel, and certain related assets from biotechnology company VBL Therapeutics.

March 1, 2023

·

4 min read

Biotech Bay

Modis Therapeutics Announces $30M Series A Financing

Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases, announced today a $30M Series A investment

October 1, 2018

·

5 min read

Policy

Modis Therapeutics Announces PRIME Designation Granted by the European Medicines Agency to MT1621 for the Treatment of TK2 Deficiency

Modis Therapeutics announced today that the European Medicines Agency (EMA) has granted PRIME (PRIority MEdicines) designation to MT1621, Modis’ investigational treatment for patients with thymidine kinase 2 deficiency (TK2d).

November 13, 2018

·

3 min read

BioForest

CytoDyn Announces the Addition of Leading Experts in Oncology, Infectious Diseases, and Neuroinflammation to its Scientific Board of Advisors; Dr. Jay Lalezari to Serve as Outside Scientific Advisor

CytoDyn Inc. announced the addition of Dr. Paul Edison, Dr. Kabir Mody, and Dr. Otto Yang to the Company’s Scientific Board of Advisors.

May 13, 2022

·

7 min read